Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Life Science Investing
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid, Triggering a $25 Million Milestone Payment Life Science Investing
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update Life Science Investing
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Life Science Investing
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Life Science Investing
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November Life Science Investing
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting Life Science Investing
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology Annual Meeting Life Science Investing
